Walvax Biotechnology Co., Ltd.
300142
株式のランク
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
株価
$1.87
時価総額
$2.98B
変化（1日）
-3.71%
変化（1年）
14.73%
国
CN
取引 Walvax Biotechnology Co., Ltd. (300142)
カテゴリー
Healthcare
Walvax Biotechnology Co., Ltd.（300142）の利益
Jun 2026 時点の利益 TTM: $33.43M
Walvax Biotechnology Co., Ltd. の最新の財務報告によると、同社の現在の利益は $33.43M です。2024 年には $25.28M の利益を上げ、これは 2023 年の利益 $84.62M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Walvax Biotechnology Co., Ltd. の利益の推移（2007 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $33.43M | 40.82% |
| 2025 | $23.74M | -6.07% |
| 2024 | $25.28M | -70.13% |
| 2023 | $84.62M | -45.47% |
| 2022 | $155.19M | 39.13% |
| 2021 | $111.54M | -46.94% |
| 2020 | $210.22M | 537.94% |
| 2019 | $32.95M | -80.85% |
| 2018 | $172.06M | -294.12% |
| 2017 | $-88.63M | -1,874.21% |
| 2016 | $5.00M | -103.67% |
| 2015 | $-136.24M | -711.67% |
| 2014 | $22.27M | 1,211.52% |
| 2013 | $1.70M | -96.04% |
| 2012 | $42.89M | 9.96% |
| 2011 | $39.01M | 40.55% |
| 2010 | $27.75M | 101.15% |
| 2009 | $13.80M | 117.38% |
| 2008 | $6.35M | 390.06% |
| 2007 | $1.30M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $3.62B | 10,720.80% |
DE
|
|
| $3.40B | 10,084.09% |
DE
|
|
| $1.72B | 5,055.23% |
JP
|
|
| $930.30M | 2,682.47% |
CH
|
|
| $1.76B | 5,177.67% |
IN
|
